APA Update: New Antidepressants Elbow Into Crowded Market
Lundbeck/Takeda unveil pivotal trial data for Brintellix (vortioxetine) in major depression, while Forest pooled analyses shed more light on levomilnacipran in subgroups. Docs don’t think the new drugs are differentiated, but since antidepressant response is so quirky, the prescribing door is still open.
You may also be interested in...
With Day 2 of the BIO convention in San Diego in full swing, major deals, academic partnerships and hot pipelines take center stage – as long as they can be discussed in the World Cup Lounge.
FDA “complete response” letter seeks another trial to better define the most tolerable dose, which could get the atypical antipsychotic to market in a better position than the original dataset.
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.